(TOVX) Theriva Biologics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOVX) Theriva Biologics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Theriva Biologics, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already includes a real preview of the actual report content, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
0 approved products
Theriva Biologics, Inc. has 0 approved products, so it has no commercial Star to place in the BCG matrix. The company is still clinical-stage, and its 2025 Form 10-K did not name any marketed therapy or product revenue. That leaves Theriva Biologics, Inc. with pipeline assets only, not a market leader.
0 disclosed commercial revenue
Theriva Biologics, Inc. disclosed 0 commercial revenue, so there is no product-sales engine to back a Star in the BCG Matrix. Stars need strong growth and clear market share leadership, but that is not visible here. With no disclosed sales base, the business fits an early-stage or question-mark profile, not a Star.
0 disclosed market share
Theriva Biologics, Inc. reports no disclosed market share because its portfolio is still in development, so it is competing for future adoption rather than defending an installed base. That makes this look unlike a current Star, which should already have visible share in a growing market. As a clinical-stage company, Theriva Biologics, Inc. still depends on trial progress, regulatory milestones, and financing, not on scaled sales.
2022 rebrand only
Theriva Biologics’ 2022 name change from Synthetic Biologics was a corporate reset, not a market-share win. In BCG terms, this is a signal shift, not a Star: no rebrand can create a leading product by itself. Its 2025 value still depends on pipeline execution, not the rename.
- 2022 rebrand: strategic repositioning
- No product leadership from naming alone
- Star status needs market growth and share
All assets clinical-stage
Theriva Biologics, Inc. has no commercial products; its pipeline is still made up of investigational, clinical-stage assets. That means these programs can become Stars later, but right now they still need Phase data, regulatory approval, and market adoption before they can drive major cash flow. In BCG terms, they sit in the build phase, not the Star phase.
- All programs remain investigational.
- No approved revenue engine yet.
- Proof, approval, and adoption still needed.
Theriva Biologics Has No Stars Yet—Still in the Build Phase
Theriva Biologics, Inc. has no commercial Stars in its BCG matrix because it reported 0 approved products and 0 commercial revenue in its 2025 Form 10-K. Its portfolio remains clinical-stage, so any future Star would depend on trial success, FDA approval, and market uptake. Right now, the company is still in the build phase, not the Star phase.
| Metric | 2025 status |
|---|---|
| Approved products | 0 |
| Commercial revenue | 0 |
| Pipeline stage | Clinical-stage |
What is included in the product
Detailed Word Document
Theriva Biologics’ BCG Matrix maps its pipeline units to guide invest, hold, or divest decisions.
Editable Excel File
One-page Theriva Biologics BCG Matrix for quick quadrant clarity and faster strategic decisions
Reference Sources
Lists credible sources behind Theriva Biologics, Inc. claims, making the analysis easier to trust, verify, and use in decisions.
Cash Cows
0 mature franchises
Theriva Biologics, Inc. shows 0 mature franchises, so it has no clear Cash Cow. Cash Cows need an established product with high share and low growth, but Theriva’s latest filings do not show a commercial franchise that fits that profile. With no durable revenue engine, the company looks more like a development-stage biotech than a mature cash generator.
0 recurring product cash
Theriva Biologics has no recurring product revenue stream, so there is nothing to harvest like a true Cash Cow. Its latest filings still show dependence on clinical-stage progress, with value tied to future trial outcomes rather than repeat sales. That makes this bucket a poor fit: no stable cash engine, no visible 2026/2025 run-rate to milk.
0 royalty income disclosed
Theriva Biologics, Inc. reports 0 royalty income disclosed, and no royalty-bearing asset is mentioned in the supplied information. That means the Company Name lacks a steady, low-cost cash stream common in biotech. With a precommercial portfolio, cash flow still depends on financing and development progress.
0 dividend-supporting asset
Theriva Biologics, Inc. has no identified dividend-supporting asset, so it is not acting like a Cash Cow. The business appears to be funding development and clinical work rather than harvesting steady profits, which means cash is more likely going into R&D than into dividends or debt service.
- No stable cash cow identified
- Cash is being used for development
- No dividend funding source shown
- Supports a cash-consumer profile
0 low-growth high-share brand
Theriva Biologics, Inc. has no true cash cow because it does not have a marketed product with a large installed base or recurring revenue stream. Low market growth only matters after share is won, and that condition is not met here. Its profile stays development-stage, so cash generation is not supported by scale or customer lock-in.
- No large installed base
- No recurring cash engine
- Low growth is not enough
- Share has not been won
Theriva Biologics Misses the Cash Cow Bucket in 2026/2025
Theriva Biologics, Inc. has no Cash Cow in 2026/2025: no marketed product, no recurring product revenue, and no disclosed royalty income. The Company Name remains a development-stage biotech, so cash is tied to R&D and trial work, not a mature profit engine. That makes the Cash Cow bucket a clear miss.
| Metric | 2026/2025 |
|---|---|
| Marketed products | 0 |
| Recurring revenue | None disclosed |
| Royalty income | 0 disclosed |
Preview Before You Purchase
Theriva Biologics, Inc. Reference Sources
The Theriva Biologics, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo content, no watermark—just the full, professionally formatted report. Once purchased, it’s ready for immediate download and use. What you see here is exactly what you get.
Dogs
SYN-006 narrow infection target
SYN-006 targets a narrow niche: preventing aGVHD and infections from carbapenem-resistant enterococci. That means no broad commercial footprint yet, and it sits in the Dogs end of Theriva Biologics, Inc.’s BCG mix. Until larger clinical data or revenue traction emerge, it stays weak on both growth and share.
SYN-007 oral beta-lactam diarrhea
SYN-007 is Theriva Biologics, Inc.’s investigational oral beta-lactam diarrhea program, aimed at reducing antibiotic-associated diarrhea from oral beta-lactam use. Its use case is narrow, so the addressable market is smaller than broader GI assets. With no disclosed 2025/2026 revenue, trial traction, or commercial sales, it fits a low-visibility Dogs profile.
SYN-005 pertussis program
SYN-005 targets both prevention and treatment of pertussis, a disease that still caused an estimated 24.1 million cases and 160,700 deaths in children under 5 in 2021, according to WHO. But Theriva Biologics, Inc. has not commercialized the program, so it has no sales base or market share. That leaves it in the Dogs bucket today.
VCN-11 follow-on oncology
VCN-11 is a follow-on oncology asset, but Theriva Biologics, Inc. has not shown late-stage or approved-product traction for it. In BCG terms, that makes it a Dogs candidate: low near-term cash generation, high development risk, and weaker strategic pull than the lead pipeline assets.
- Follow-on cancer program
- No late-stage proof given
- No approved-product revenue
- Trailing, uncertain asset
0 commercial proof points
Theriva Biologics, Inc. shows 0 commercial proof points: the supplied profile lists no marketed drug, so there is no sales base to absorb weak pipeline assets. In BCG terms, that leaves the portfolio in Dog territory because nothing has proven demand, pricing power, or recurring revenue.
That matters because a Dog can still burn cash even when development data look promising; without an approved product, there is no offset from operating income. The key signal is simple: no commercial asset, no commercial cushion.
- No marketed drug in profile
- 0 revenue offset from sales
- Weak programs stay exposed
- No commercial proof to date
Theriva’s Pipeline Dogs: No Sales, No Traction, No Turnaround Yet
Theriva Biologics, Inc.’s Dogs are the noncommercial pipeline assets: SYN-006, SYN-007, SYN-005, and VCN-11. With no marketed drug, no disclosed 2025/2026 revenue, and no late-stage or approved-product traction, they have weak share and low cash generation. The group stays in Dog territory until one asset proves sales or phase-3 strength.
| Asset | Dog signal |
|---|---|
| SYN-006 | Niche use, no sales |
| SYN-007 | Narrow market, no revenue |
| SYN-005 | Uncommercialized, no share |
| VCN-11 | No late-stage traction |
Question Marks
SYN-004 Phase 1b 2a
SYN-004 is a Phase 1b/2a question mark because it targets a big unmet need but still lacks proof of clinical impact. It is designed to break down intravenous beta-lactam antibiotics in the gut, aiming to cut microbiome damage, CDI, AMR, and aGVHD. Theriva's Washington University School of Medicine trial tie-up adds credibility, but the asset still needs human data to show value.
SYN-020 oral intestinal alkaline phosphatase
SYN-020 is an oral recombinant intestinal alkaline phosphatase aimed at localized GI and systemic diseases, so its market reach could be wide. But adoption is still unproven, and Theriva Biologics, Inc. has not shown commercial demand yet. In a BCG view, that fits a Question Mark: high potential, low validation.
VCN-01 pancreatic cancer
VCN-01 in pancreatic cancer fits the Question Mark box: Theriva Biologics is pushing it into a high-need market where pancreatic ductal adenocarcinoma still has a 5-year relative survival of about 13%, but the asset has no reported market share yet. In the U.S., about 67,440 new pancreatic cancer cases and 51,980 deaths were projected for 2025, showing a large and growing pool. The upside is real, but the win is not proven.
VCN-01 head and neck, colorectal, retinoblastoma
VCN-01 is a clear Question Mark in Theriva Biologics, Inc.’s BCG Matrix because the same asset is being tested across head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. That multi-indication setup lifts optionality, but it also shows the program is still looking for the best commercial fit and has not yet proved a single winning market.
Three indications = more shots on goal
Still pre-commercial, so market fit is unproven
Best path depends on strongest clinical signal
SYN-005 and SYN-007 growth optionality
SYN-005 and SYN-007 are classic Question Marks for Theriva Biologics, Inc.: they target infectious-disease niches with clear unmet need, but they still need cash and trial work before they can earn revenue. If clinical data turn positive, each program could move up in strategic value fast; for now, they are spending R&D dollars without commercial return.
- High unmet need
- No near-term sales
- Positive data could re-rate value
- Current drag on development spend
Theriva’s Pipeline: High-Risk Question Marks with Big Upside Potential
Theriva Biologics, Inc. question marks are early-stage assets with clear unmet need but no proven sales. VCN-01 stands out in pancreatic cancer, where U.S. 2025 cases were projected at 67,440 and deaths at 51,980, but market share is still zero. SYN-004, SYN-005, SYN-007, and SYN-020 all need stronger clinical proof before they can move beyond high-risk, high-upside status.
| Asset | BCG role | Key signal |
|---|---|---|
| VCN-01 | Question Mark | 67,440 U.S. cases in 2025 |
| SYN-004 | Question Mark | Phase 1b/2a only |
| SYN-020 | Question Mark | No commercial demand shown |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.